RealTime Dynamix™: AS and Nr-AxSpA Q2 2017

US rheumatologists highlight difficulties in axial spondyloarthropathy diagnosis and timely referrals, according to RealTime Dynamix: Ankylosing Spondylitis and Non Radiographic Axial Spondyloarthropathy Q2. Despite the possibility of a large undiagnosed population of patients with AS or nr-axSpA, when patients are treated, US rheumatologists report high satisfaction with the existing TNF-inhibitors, such as AbbVie’s Humira, Amgen’s Enbrel, and Janssen’s Remicade,

Click the button below to view highlights from this quarter 2 report:

RTD: AS and Nr-AxSpA Q2 Spotlight

2017-08-07T17:13:24+00:00